Future directions of cytokine hypothesis in depression: 'NLRP3 inflammasome';Depresyon ve sitokin hipotezinde yeni ufuklar: 'NLRP3 inflamazomu'

Klinik Psikofarmakoloji Bulteni

Volumn 23, Issue 3, 2013, Pages 280-288

  Sahin, Ceren ^a   Aricioglu, Feyza ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Cytokine; Depression; IL 1 ; Inflammasome; Microglia; NLRP3; Pro inflammatory

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CRYOPYRIN; CYTOKINE; ETANERCEPT; GLIBENCLAMIDE; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 1BETA; MICRORNA 223; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X7 RECEPTOR; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

AUTOPHAGY; BEHAVIOR DISORDER; DEPRESSION; HIPPOCAMPUS; HUMAN; IMMUNE RESPONSE; META ANALYSIS (TOPIC); MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PREVALENCE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84885027952     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5455/bcp.20130927070724     Document Type: Review

References (69)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997; 349(9064): 498-1504.
2. Iwata M, Ota KT, Duman RS. The inflammasome: Pathways linking psychological stress, depression and systemic illnesses. Brain Behaviour and Immunity 2013; 31: 105-14.
3. Pralong E, Magistretti P, Stoop R. Cellular perspectives on the glutamate-monoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders. Prog Neurobiol 2002; 67(3): 173-202.
4. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012; 62(1): 63-77.
5. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR/D report. Am J Psychiatry 2006; 163(11): 1905-17.
6. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013; 246: 199-229.
7. Robbins TW, Arnsten AF. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 2009; 32: 267-87.
8. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005; 58(3): 175-89.
9. Simona NM, McNamara K, Chowa CW, Maser RS, Papakostas GI, Pollack MH, et al. A detailed examination of cytokine abnormalities in major depressive disorder European Neuropsychopharmacology 2008; 18(3): 230-3.
10. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67(5): 446-57.
11. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011; 36(12): 2452-9.
12. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002; 5(4): 401-12.
13. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367(9504): 29-35.
14. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007; 55(5): 453-62.
15. Jones KA, Thomsen C. The role of the innate immune system in psychiatric disorders. Molecular and Cellular Neuroscience 2013; 53: 52-62.
16. Katsuura G, Arimura A, Koves K, Gottschall PE. Involvement of organum vasculosum of lamina terminalis and preoptic area in interleukin 1 beta-induced ACTH release. Am J Physiol 1990; 258(1): 163-71.
17. Skinner RA, Gibson RM, Rothwell NJ, Pinteaux E, Penny JI. Transport of interleukin-1 across cerebromicrovascular endothelial cells. Br J Pharmacol 2009; 156(7): 1115-23.
18. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Neuroimmunol 1993; 47(2): 169-76.
19. Banks WA, Erickson MA The blood-brain barrier and immune function and dysfunction. Neurobiol Dis 2010; 37(1): 26-32.
20. Watkins LR, Goehler LE, Relton JK, Tartaglia N, Silbert L, Martin D, et al. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication. Neurosci Lett 1995; 183(1-2): 27-31.
21. Shaftel SS, Carlson TJ, Olschowka JA, Kyrkanides S, Matousek SB, O'Banion MK. Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J Neurosci 2007; 27(35): 9301-9.
22. Pitossi F, del Rey A, Kabiersch A, Besedovsky H. Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J Neurosci Res 1997; 48(4): 287-98.
23. French RA, VanHoy RW, Chizzonite R, Zachary JF, Dantzer R, Parnet P, et al. Expression and localization of p80 and p68 interleukin-1 receptor proteins in the brain of adult mice. J Neuroimmunol 1999; 93(1-2): 194-202.
24. Frost P, Barrientos RM, Makino S, Wong ML, Sternberg EM. IL-1 receptor type I gene expression in the amygdala of inflammatory susceptible Lewis and inflammatory resistant Fischer rats. J Neuroimmunol 2001; 121(1-2): 32-9.
25. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, et al. Synaptic pruning by microglia is necessary for normal brain development. Science 2011; 333(6048): 1456-8.
26. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev 2011; 91(2): 461-553.
27. Nair A, Bonneau RH. Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J Neuroimmunol 2006; 171(1-2): 72-85.
28. Chang Y, Lee JJ, Hsieh CY, Hsiao G, Chou DS, Sheu JR. Inhibitory effects of ketamine on lipopolysaccharide-induced microglial activation. Mediators Inflamm 2009; 705379: 1-7.
29. Horikawa H, Kato TA, Mizoguchi Y, Monji A, Seki Y, Ohkuri T, et al. Inhibitory effects of SSRIs on IFN-γ induced microglial activation through the regulation of intracellular calcium. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(7): 1306-16.
30. Liu D, Wang Z, Liu S, Wang F, Zhao S, Hao A. Anti-inflammatory effects of fluoxetine in lipopolysaccharide-stimulated microglial cells. Neuropharmacology 2011; 61(4), 592-9.
31. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med 2011; 73(2): 114-26.
32. Berkenbosch F, Van Oers J, del Rey A, Tilders F, Besedovsky H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 1987; 238(4826): 524-6.
33. Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann. N. Y. Acad. Sci. 2009; 1179: 86-105.
34. Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993; 150: 1189-93.
35. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995; 15(3): 1768-77.
36. Wellman CL. Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration. J Neurobiol 2001; 49(3): 245-53.
37. Bluthe RM, Pawlowski M, Suarez S, Parnet P, Pittman Q, Kelley KW, et al. Synergy between tumor necrosis factor alpha and interleukin-1 in the induction of sickness behavior in mice. Psychoneuroendocrinology 1994; 19(2): 197-207.
38. Lacosta S, Merali Z, Anisman H. Influence of interleukin-1beta on exploratory behaviors, plasma ACTH, corticosterone, and central biogenic amines in mice. Psychopharmacology 1998; 137(4): 351-61.
39. Bonaccorso S, Maier SF, Meltzer HY, Maes M. Behavioral changes in rats after acute, chronic and repeated administration of interleukin-1beta: relevance for affective disorders. J Affect Disord 2003; 77(2): 143-8.
40. Wilhelm CJ, Murphy-Crews A, Menasco DJ, Huckans MS, Loftis JM. Corticotropin releasing factor-1 receptor antagonism alters the biochemical, but not behavioral effects of repeated interleukin-1beta administration. Neuropharmacology 2012; 62(1): 313-21.
41. Cole J, Costafreda SG, McGuffin P, Fu CH. Hippocampal atrophy in first episode depression: a meta-analysis of magnetic resonance imaging studies. J Affect Disord 2011; 134(1-3): 483-7.
42. O'Connor JC, Lawson MA, André C, Moreau M, Lestage J, Castanon N. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2, 3-dioxygenase activation in mice. Mol Psychiatry 2009; 14(5): 511-22.
43. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 2012; 35(1): 47-56.
44. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 2011; 8(94): 1-9.
45. Salvadore G, Cornwell BR, Sambataro F, Latov D, Colon-Rosario V, Carver F, et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacol 2010; 35(7): 1415-22.
46. Santello M, Volterra A. TNFα in synaptic function: switching gears. Trends Neurosci 2012; 35(10): 638-47.
47. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990; 185(1): 1-10.
48. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20(3): 319-25.
49. Petrilli V, Papin S, Tschopp J. The inflammasome. Curr Biol 2005; 9; 15(15): 581.
50. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006; 126(4): 659-62.
51. Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1β generation. Clin Exp Immunol 2007; 147(2): 227-35.
52. Hanamsagar R, Torres V, Kielian T. Inflammasome activation and IL-1beta/IL-18 processing are influenced by distinct pathways in microglia. J Neurochem 2011; 119(4): 736-48.
53. Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J cell biol 2009; 187(1): 61-70.
54. Chakraborty S, Kaushik DK, Gupta M, Basu A. Inflammasome signaling at the heart of central nervous system pathology. Journal of Neuroscience Research 2010; 88(8): 1615-31.
55. Vladimer GI, Marty-Roix R, Ghosh S, Weng D, Lien E. Inflammasome and host defenses against bacterial infections. Current Opinion in Microbiology 2013; 16(1): 23-31.
56. Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. Embo J 2006; 25(21): 5071-82.
57. Pelegrin P, Surprenant A. Pannexin-1 couples to maitotoxin and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J Biol Chem 2007; 282(4): 2386-94.
58. Stehlik C, Dorfleutner A. COPs and POPs: modulators of inflammasome activity. J Immunol 2007; 179(12): 7993-8.
59. Haneklaus M, O'Neill LA, Coll RC. Modulatory mechanisms controlling the NLRP3 inflmmasome in inflammation: recent developments. Current Opinion in Immunology 2013; 25(1): 40-5.
60. Harris J. Autophagy and cytokines. Cytokine 2011; 56(2): 140-4.
61. Harris J. Autophagy and IL-1 family cytokines. Frontiers in Immunology 2013; 4(83): 1-6.
62. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production. Nature 2008; 456(7219): 264-8.
63. Harris J, Hartman M, Roche C, Zeng SG, O'Shea A, Sharp FA, et al. Autophagy controls IL-1β secretion by targeting pro-IL-1β for degradation. J Biol Chem 2011; 286(11): 9587-97.
64. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, et al. Autophagy proteins regulate innate immune response by inhibiting by the NALP3 inflammasome-mediated mitochondrial DNA release. Nat Immunol 2011; 12(3): 222-30.
65. Sorbara MT, Girardin SE. Mitochondrial ROS fuel the inflammasome. Nature 2011; 21(4): 558-60.
66. Zou R, Yazdi AS, Menu P, Tschopp J. A rol for mitochondria in NLRP3 inflammasome activation. Nature 2010; 469(7329): 221-5.
67. Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, Hornung V. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol 2012; 189(8): 4175-81.
68. Arulkumaran N, Unwin RJ, Tam FW. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs 2011; 20(7): 897-915.
69. Pereira VS, Casarotto PC, Hiroaki-Sato VA, Sartim AG, Guimaraes FS, Joca S RL. Antidepressant and anticompulsive-like effects of purinergic receptor blockade: Involvement of nitric oxide. European Neuropsychopharmacology 2013 (in press).